Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity

Summary

The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.

Eligibility

Inclusion Criteria:

* Provide informed consent
* Have a BMI ≥ 28 kg/m2
* Be of African American ancestry
* Meet diagnostic criteria for DKA. Diagnostic criteria for DKA will include a plasma glucose \> 250 mg/dl, a venous pH \< 7.30, a serum bicarbonate \< 18 mmol/l, and serum ketones (beta-hydroxy butyrate) \> 1.5 mmol/L.

Exclusion Criteria:

* Significant medical or surgical illness including but not limited to myocardial ischemia, congestive heart failure, chronic peripheral venous insufficiency, chronic renal insufficiency, liver insufficiency (serum transaminases 3 times the upper limit of normal) and acute or chronic infectious processes
* Have recognized uncontrolled endocrine disorders such as hypercortisolism, acromegaly, or hyperthyroidism
* Anemia (hemoglobin \< 12.5 g/dL for men, \<11.5 gm/dL for women), bleeding disorders, or abnormalities in coagulation studies
* Pregnant
* Diagnosis of diabetes \> 90 days before the presentation of DKA
* Unable to give consent

Conditions2

Interventions1

Locations2 sites

Find trials near these locations

Related trials

• Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes — Mostafa Bahaa
• Glycemic Variations During the Menstrual Cycle in Women With Type 1 Diabetes — Institut de Recherches Cliniques de Montreal
• Insulin Sensitivity After Breast Cancer — University of Copenhagen
• Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes — Nanjing Medical University
• DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes — Ohio State University
• FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) — Sanofi
• Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes — Thomas Jefferson University
• Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2) — Thomas Jefferson University

Browse More Trials